- Home
- CLYM
CLYM
CLIMB BIO INC
as 11-20-2024 4:00pm EST
Stocks
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 242.8M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 314.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.35 - $11.55 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest CLIMB BIO INC News
CLYM Breaking Stock News: Dive into CLYM Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
10 days ago
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
GlobeNewswire
21 days ago
Climb Bio to Present at Upcoming Investor Conferences
GlobeNewswire
a month ago
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
GlobeNewswire
a month ago
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
GlobeNewswire
2 months ago
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
Compare CLYM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLYM CLIMB BIO INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.